冷沉淀对改善肿瘤患者凝血功能异常效果分析

Analysis on the Role of Cryoprecipitate in Improvement of Coagulation Abnormalities in Patients with Tumors

目的通过冷沉淀在凝血功能异常的肿瘤患者中的输注,了解不同次数和不同剂量对肿瘤患者凝血常规异常的纠正效果。方法 对15例肿瘤患者在第一次凝血常规结果明显异常时,给予冷沉淀治疗,连续1~5 d,每天都监测血小板及凝血功能的各项指标。结果15例肿瘤患者在冷沉淀给予过程中,凝血常规指标除PLT外,其它指标随着剂量和次数的变化,差异有统计学意义。结论肿瘤患者在凝血常规明显异常时合理使用冷沉淀可以改善其凝血障碍,还可以减少血浆的输注量。但补充冷沉淀的次数及剂量要根据凝血常规的结果再结合患者的病情来具体定夺。

Objective To explore the correction effect of cryoprecipitate on coagulation abnormalities in patients with tumors. Methods Fifteen patients with tumors were treated with cryoprecipitate when they showed coagulation abnormalities for the first time.The treatment last for 1～5 days,and the blood platelet and blood coagulation function were monitored each day of the treatment. Results There were statistically significant differences in the coagulation indexes except PLT among 15 tumors patients during the period of treatment with different frequencies and different doses of cryoprecipitate. Conclusions Rational use of cryoprecipitate can improve hemoglutination function barrier and reduce the infusion of blood plasma when tumor patients present obvious coagulation abnormalities.But the frequency and the dose of cryoprecipitate supplement should decide in accordance with the monitoring result of conventional blood coagulation combined with the patient＇s actual condition.